Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
28 sept. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its...